Please use this identifier to cite or link to this item:
http://ir.mu.ac.ke:8080/jspui/handle/123456789/4945
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Were, Edwin O. | - |
dc.contributor.author | Heffron, Renee | - |
dc.contributor.author | Mugo, Nelly R. | - |
dc.contributor.author | Celum, Connie | - |
dc.contributor.author | Mujugira, Andrew Ambogo | - |
dc.contributor.author | Bukusi, Elizabeth A. | - |
dc.contributor.author | Baeten, Jared M. | - |
dc.date.accessioned | 2021-07-27T11:41:59Z | - |
dc.date.available | 2021-07-27T11:41:59Z | - |
dc.date.issued | 2014 | - |
dc.identifier.uri | http://dx.doi.org/10.1097/QAD.0000000000000313 | - |
dc.identifier.uri | http://ir.mu.ac.ke:8080/jspui/handle/123456789/4945 | - |
dc.description.abstract | Background: There is a paucity of data on the effect of antiretroviral medications on male fertility. Couples affected by HIV-1 often have fertility intentions, and antiretroviral medications, as both treatment of HIV-1-infected persons and pre-exposure prophylaxis (PrEP) for uninfected persons, are part of peri-conception risk reduction. Methods: Within a randomized, placebo-controlled trial of daily oral tenofovir disoproxil fumarate (TDF) and combination emtricitabine (FTC)/TDF PrEP for HIV-1 prevention conducted among heterosexual HIV-1-serodiscordant couples, we assessed the impact of TDF and FTC/TDF use on male fertility, measured as incident pregnancy in female partners of men assigned to PrEP vs. placebo. Results: Of the 2962 HIV-1-uninfected men partners, 986 were randomized to TDF, 1013 to FTC/TDF, and 963 to placebo. The overall pregnancy incidence in their HIV-1-infected female partners was 12.9 per 100 person-years and did not differ significantly across the study arms (13.2 TDF, 12.4 FTC/TDF, 13.2 placebo). The frequency of live births, pregnancy losses, and gestational age at birth or loss was also statistically similar in the three randomization groups. Conclusion: TDF and FTC/TDF, when used as PrEP by HIV-1-uninfected men, did not adversely affect male fertility or pregnancy outcomes. | en_US |
dc.language.iso | en | en_US |
dc.publisher | NIH Public Access | en_US |
dc.subject | Pre-exposure prophylaxis | en_US |
dc.subject | Peri-conception risk | en_US |
dc.title | Pre-exposure prophylaxis (PrEP) does not affect the fertility of HIV-1 uninfected men | en_US |
dc.type | Article | en_US |
Appears in Collections: | School of Medicine |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.